Cancer Research and Treatment

A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang

British Journal of Cancer.2023; 129(2): 275. CrossRef

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule

Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi

Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours

Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano

Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review

Charlotte Margareta Brinch, Ninna Aggerholm-Pedersen, Estrid Hogdall, Anders Krarup-Hansen

Critical Reviews in Oncology/Hematology.2022; 172: 103650. CrossRef

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature

Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson

Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors

Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Seiichi Hirota, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki

International Journal of Clinical Oncology.2022; 27(7): 1164. CrossRef

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review

Vahe Khachatryan, Asmaa Muazzam, Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, Greeshma N Gaddipati, Maria Mukhtar, Mohammed J Alzubaidee, Raga Sruthi Dwarampudi, Sheena Mathew, Sumahitha Bichenapally, Lubna Mohammed

CT Image Examination Based on Virtual Reality Analysis in Clinical Diagnosis of Gastrointestinal Stromal Tumors

Zhiying Wang, Qiaoyan Qu, Ke Cai, Ting Xu, Zhihan Lv

Journal of Healthcare Engineering.2021; 2021: 1. CrossRef

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?

Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman, Joanna Zawitkowska

International Journal of Molecular Sciences.2021; 22(21): 12089. CrossRef

Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

International Journal of Molecular Sciences.2020; 21(21): 8232. CrossRef

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study

Chia‑Hsiang Hu, Chun‑Nan Yeh, Jen‑Shi Chen, Chun‑Yi Tsai, Shang‑Yu Wang, Chi‑Tung Cheng, Ta‑Sen Yeh

Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers

Ganfeng Xie, Yuzhu Gong, Shuang Wu, Chong Li, Songtao Yu, Zhe Wang, Jianfang Chen, Quanfeng Zhao, Jianjun Li, Houjie Liang

Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients

Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea G. Barbo, Heather Y. Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Ne

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib